Common Inpatient Drugs That Cause QT Prolongation
The most common inpatient medications causing QT prolongation can be remembered by the "anti's": antibiotics (macrolides and fluoroquinolones), antifungals, antiarrhythmics, antipsychotics/antidepressants, antiemetics, and analgesics (including methadone). 1
High-Risk Drug Categories in the Inpatient Setting
Antiarrhythmic Agents (Highest Risk)
- Sotalol, dofetilide, ibutilide - TdP incidence 1-10% 2
- Amiodarone - requires constant monitoring 3
- Quinidine, procainamide, disopyramide - older agents with 1-10% TdP risk 2
Antibiotics
Macrolides:
- Erythromycin - highest risk among macrolides 1
- Clarithromycin - significant association with QTc prolongation 4
- Azithromycin - lowest risk among macrolides (9.6% of cases) 1, 5
Fluoroquinolones:
- Ciprofloxacin - requires dose reduction in renal disease 1
- Moxifloxacin - very low TdP incidence (1:100,000 to 1:1,000) but still prolongs QT 2
Beta-lactam combinations:
Psychiatric Medications
Antipsychotics:
Antidepressants:
- Citalopram and escitalopram - highest risk among SSRIs 1
- Paroxetine and sertraline - negligible risk (safer alternatives) 1
Antiemetics
Analgesics
Antifungals
Gastrointestinal Medications
- Proton pump inhibitors - most common cause in one study
- Esomeprazole - 46.5% of non-cardiac drug-induced QTc prolongation cases 5
Cardiovascular Medications (Non-Antiarrhythmic)
- Glyceryl trinitrate - significant association 4
- Diuretics (furosemide) - both direct QT effect and indirect via electrolyte depletion 4
Risk Stratification Framework
Critical risk threshold: QTc ≥500 ms or increase >60-70 ms from baseline, particularly when rapid 1
Patient-specific risk factors that amplify drug effects:
- Heart failure - OR 4.98 for QTc prolongation 5
- Female sex 1
- Elderly patients 1
- Electrolyte disturbances (hypokalemia, hypomagnesemia) 1
- Renal dysfunction - many QT-prolonging drugs accumulate 1
- Structural heart disease 1
- Bradycardia 4
Important Intraclass Distinctions
The evidence emphasizes that not all drugs within a class carry equal risk 1:
- Among macrolides: erythromycin > clarithromycin > azithromycin
- Among SSRIs: citalopram/escitalopram >> paroxetine/sertraline (essentially safe)
- Safe antibiotic alternatives: penicillins and cephalosporins do not prolong QT 1
Critical Drug Interactions
High-risk combinations in the inpatient setting:
- Psychotropic drugs + antibiotics + diuretics 6
- Multiple QT-prolonging agents simultaneously 1
- QT-prolonging drugs in patients with renal failure (drug accumulation) 1
Practical Monitoring Approach
When to obtain ECG:
- Before initiating high-risk drugs (sotalol, dofetilide, methadone) 1
- When adding a second QT-prolonging drug 1
- In presence of electrolyte disturbances 1
- After each dose change of high-risk agents 1
When ECG monitoring is unnecessary:
- Low-risk patient starting low-risk drug (e.g., sertraline in healthy person) 1
Common Pitfall
The 2023 Canadian guidelines emphasize that when a patient is already on a QT-prolonging drug and needs an antibiotic, it is preferable to choose a non-QT-prolonging alternative (penicillin/cephalosporin) rather than adding a fluoroquinolone or macrolide and just monitoring the ECG 1. This proactive substitution strategy is safer than reactive monitoring.
Essential monitoring when QT-prolonging drugs are used: electrolytes and renal function, especially with concurrent diuretic use or renal impairment 1.
The evidence consistently shows that while many drugs prolong QT, actual TdP incidence varies dramatically—from 1-10% with antiarrhythmics to extremely rare with drugs like moxifloxacin 2. However, risk increases substantially with polypharmacy, electrolyte disturbances, and patient-specific factors 2, 6, 3.